Drug Information

Drug General Information
Drug ID
D01NAP
Former ID
DNCL002253
Drug Name
MM-151
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [549340]
Company
Merrimack Pharmaceuticals
Target and Pathway
Target(s) Receptor protein-tyrosine kinase erbB-3 Target Info Modulator [532567]
KEGG Pathway ErbB signaling pathway
Calcium signaling pathway
Endocytosis
Proteoglycans in cancer
MicroRNAs in cancer
NetPath Pathway TNFalpha Signaling Pathway
PANTHER Pathway Cadherin signaling pathway
EGF receptor signaling pathway
Pathway Interaction Database ErbB2/ErbB3 signaling events
ErbB receptor signaling network
a6b1 and a6b4 Integrin signaling
WikiPathways ErbB Signaling Pathway
Apoptosis-related network due to altered Notch3 in ovarian cancer
Signaling Pathways in Glioblastoma
miR-targeted genes in muscle cell - TarBase
Heart Development
References
Ref 549340Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035447)
Ref 532567MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.